levophed

Developed for: ischemic stroke · acute hypotension · traumatic brain injury
Investigated by: Johns Hopkins University · National Institutes of Health (NIH)

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	US (FDA)	LEVOPHED	—	1950-07-13	fda.gov ↗

Trials 1 · a red edge is where a trial was stopped

today

US approved 1950

NCT00227448 · Ph 2

19491950195119521953195419551956195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT00227448	Jun 2003 → Apr 2005	ischemic stroke	Johns Hopkins University	Completed	No outcome recorded

Also used as a comparator or background therapy in 2 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 41 trial
Phase 4	NCT05502146 Comparator	Aug → Oct 2022	acute hypotension, local anesthetic poisoning	Mersin University	Completed	No outcome recorded
Phase not applicable1 trial
—	NCT00795366 Comparator	Sep 2008 → Sep 2014	traumatic brain injury	University of Miami	Completed	No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	levophed	“levophed, dopamine, phenylephrine)” NCT00795366 ↗ 1 NCT00227448 ↗
Known as	Noradrenaline Bitartrate	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05502146 ↗
Action	Activate	“Norepinephrine is an alpha adrenergic agonist with weak beta adrenergic agonistic activity” NCT05502146 ↗
Route	Intravenous	“intravenous levophed” NCT00227448 ↗